Synapse

← Atherosclerosis Plus

Papers in Atherosclerosis Plus

Page 2 · newest first

  1. LDL-C lowering in patients treated with bempedoic acid in a real-world cohortAtherosclerosis Plus · 2026
  2. Pre-procedural C-reactive protein levels and carotid or intracranial artery restenosis: A systematic review and meta-analysisAtherosclerosis Plus · 2026
  3. Prelamin A accumulation overlaps increased vascular calcification in peripheral artery disease and regulates vascular smooth muscle cells mineralization in diabetes mellitusAtherosclerosis Plus · 2026
  4. Statin treatment in routine clinical practice: Insights from the STATRIP physician surveyAtherosclerosis Plus · 2026
  5. Bisphosphonates use is associated with increased coronary artery calcification in the general population: The Rotterdam studyAtherosclerosis Plus · 2026
  6. Poecilobdella manillensis ameliorates atherosclerosis by inhibiting endothelial cell pyroptosisAtherosclerosis Plus · 2025
  7. Innate immune cell function in statin-treated patients with severe hypercholesterolemia is comparable to normocholesterolemic individuals: A cross-sectional studyAtherosclerosis Plus · 2025
  8. Layered plaque in patients with chronic coronary syndromeAtherosclerosis Plus · 2025
  9. Neural network model outperforms conventional equations in LDL cholesterol estimation: A comparative study of 188,887 Chinese individuals with focus on hypertriglyceridemiaAtherosclerosis Plus · 2025
  10. Characterization of selected LDLR substitutions in patients with familial hypercholesterolemiaAtherosclerosis Plus · 2025
  11. Midlife ICAM-1 levels may predict cardiovascular disease and cognitive decline in latelife: Insights from the HeartSCORE studyAtherosclerosis Plus · 2025
  12. Inclisiran for fast-track lipid-lowering treatment early after an acute coronary syndrome: a pilot studyAtherosclerosis Plus · 2025
  13. Demographic and regional trends of mortality in patients with cardiovascular disease and liver cirrhosis in the United States between 1999 and 2019Atherosclerosis Plus · 2025
  14. The association between dolutegravir based first-line regimens and dyslipidemia among adults living with HIV on follow-up at health facilities in Hawassa city administration, Sidama region: a cross-sectional studyAtherosclerosis Plus · 2025
  15. Effect of lipid-lowering medications on oxidized phospholipids in individuals with elevated LIPOPROTEIN(a)Atherosclerosis Plus · 2025
  16. Inclisiran in a real-world single-center registry of patients with very high atherosclerotic cardiovascular riskAtherosclerosis Plus · 2025
  17. Emerging cytokines contribute to the clinical manifestation of carotid artery plaque formation and stability in patients with diabetesAtherosclerosis Plus · 2025
  18. Lp(a) in daily clinical routine: risk-factor for both cardiovascular events and heart-failure? A retrospective analysis of the Luebeck Lp(a) heart-failure (HF) registry in patients after myocardial infarctionAtherosclerosis Plus · 2025
  19. Comparative 10-year atherosclerotic cardiovascular disease risk in Ethiopian HIV patients on first-line versus second-line combined antiretroviral therapyAtherosclerosis Plus · 2025
  20. Proposed lipidology and preventive cardiology research priorities in Africa; Results of a Delphi surveyAtherosclerosis Plus · 2025
  21. Association of uric acid with all-cause mortality in acute coronary syndrome patients with T2DMAtherosclerosis Plus · 2025
  22. The role and mechanism of PGC-1α in oxLDL-induced ferroptosis of vascular endothelial cellsAtherosclerosis Plus · 2025
  23. Association of dietary preferences with cardiovascular disease: a Mendelian randomization studyAtherosclerosis Plus · 2025
  24. Plasma apolipoprotein concentrations and occurrence of cardiovascular events in the general population: an exploratory analysisAtherosclerosis Plus · 2025
  25. Trends of atherosclerosis-related mortality in adults with diabetes: A cross-sectional analysis of U.S. national dataAtherosclerosis Plus · 2025
  26. ApoE [−/−] CA1-overexpressing knock-in mice aggravated atherosclerosis by increasing M1 macrophagesAtherosclerosis Plus · 2025
  27. Real-world management of hypercholesterolemia in patients after acute coronary syndrome in GreeceAtherosclerosis Plus · 2025
  28. HDL-replacement therapy: From traditional to emerging clinical applicationsAtherosclerosis Plus · 2025
  29. Safety and efficacy of edoxaban monotherapy after bioabsorbable polymer everolimus-eluting stent implantation in a human-like coronary atherosclerotic porcine modelAtherosclerosis Plus · 2025
  30. “Inclisiran: Early LDL-C target achievement in a real-life population”Atherosclerosis Plus · 2025
  31. Anti-atherosclerotic effects of natural compounds targeting lipid metabolism and inflammation: Focus on PPARs, LXRs, and PCSK9Atherosclerosis Plus · 2024
  32. Impact of NAFLD-related SNPs on the carotid atherosclerosis development; a five-year prospective observational studyAtherosclerosis Plus · 2024
  33. HDL-associated vitamin D binding protein levels are inversely associated with necrotic plaque burden in psoriasisAtherosclerosis Plus · 2024
  34. Emerging oral therapeutic strategies for inhibiting PCSK9Atherosclerosis Plus · 2024
  35. Disparities in patterns and outcomes of dyslipidemic patients with acute coronary syndrome: A tertiary cardiac center registryAtherosclerosis Plus · 2024
  36. Familial hypercholesterolemia – Targeted whole gene sequencing as a diagnostic approachAtherosclerosis Plus · 2024
  37. A cross-tissue transcriptome-wide association study identifies WDPCP as a potential susceptibility gene for coronary atherosclerosisAtherosclerosis Plus · 2024
  38. Adherence to the Healthy Nordic Food Index is associated with reduced plasma levels of inflammatory markers in patients with heterozygous familial hypercholesterolemiaAtherosclerosis Plus · 2024
  39. A collaborative effort across Africa to investigate risk factors and outcomes of premature acute coronary syndrome: Protocol for the EAS Lipid Registry of Africa (LIPRA)Atherosclerosis Plus · 2024
  40. Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trialsAtherosclerosis Plus · 2024
  41. Lipoprotein(a) and the atherosclerotic burden – Should we wait for clinical trial evidence before taking action?Atherosclerosis Plus · 2024
  42. Coronary artery calcification score and 19 biomarkers on cardiovascular events; a 10-year follow-up DanRisk substudyAtherosclerosis Plus · 2024
  43. Eligibility for marine omega-3 fatty acid supplementation after acute coronary syndromesAtherosclerosis Plus · 2024
  44. The pro-atherogenic enzyme PAPP-A is active in eluates from human carotid and femoral atherosclerotic plaquesAtherosclerosis Plus · 2024
  45. Extreme founder effect associated with hyperglycemia and hyperlipidemia on the island of NIAS/IndonesiaAtherosclerosis Plus · 2024
  46. Associations of very low Lipoprotein(a) levels with risks of new-onset diabetes and non-alcoholic liver diseaseAtherosclerosis Plus · 2024
  47. Lipoprotein(a) in children and adolescents with genetically confirmed familial hypercholesterolemia followed up at a specialized lipid clinicAtherosclerosis Plus · 2024
  48. NAD+ metabolism and therapeutic strategies in cardiovascular diseasesAtherosclerosis Plus · 2024
  49. Trends in cardiovascular disease among Inuit in Greenland from 1994 to 2021Atherosclerosis Plus · 2024
  50. Carotid intima-medial thickness in patients with severe hypertriglyceridemiaAtherosclerosis Plus · 2024